DOI QR코드

DOI QR Code

Cost-effectiveness Analysis of Cervical Cancer Screening Strategies Based on the Papanicolaou Smear Test in Korea

  • Ko, Min Jung (Division for Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency) ;
  • Kim, Jimin (Division for Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency) ;
  • Kim, Younhee (Institute of Health and Environment and School of Public Health, Seoul National University) ;
  • Lee, Yoon Jae (Department of Oriental Gynecology, CHA Bundang Medical Center, CHA University) ;
  • Hong, Sung Ran (Department of Pathology, Cheil General Hospital & Women's Healthcare Center, Catholic Kwandong University) ;
  • Lee, Jae Kwan (Department of Gynecology, Korea University Guro Hospital)
  • 발행 : 2015.04.03

초록

Background: Despite the increasing number of screening examinations performed for cervical cancer utilizing the Papanicolaou smear test (Pap test), few studies have examined whether this strategy is cost-effective in Korea. Objective: This study was conducted to evaluate the cost-effectiveness of cervical cancer screening strategies incorporating the Pap test based on age at the start and end of screening as well as screening interval. Materials and Methods: We designed four alternative screening strategies based on patient age when screening was started (20 or 30 years) and discontinued (lifetime, 79 years). Each strategy was assessed at screening intervals of 1, 2, 3, or 5 years. A Markov model was developed to determine the cost-effectiveness of the 16 possible cervical cancer screening strategies, and this was evaluated from a societal perspective. The main outcome measures were average lifetime cost, incremental quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER). Results: Compared with various strategies comprising younger starting age, discontinuation age, and longer screening intervals, strategies employing annual screening for cervical cancer starting at a target age of 30 years and above were the most cost-effective, with an ICER of 21,012.98 dollars per QALY gained (with a Korean threshold of 30,000,000 KRW or US$27,272). Conclusions: We found that annual screening for cervical cancer beginning at a target age of 30 years and above is most cost-effective screening strategy. Considering the potential economic advantages, more intense screening policies for cervical cancer might be favorable among countries with high rates of cervical cancer and relatively low screening costs.

키워드

참고문헌

  1. Andrae B, Kemetli L, Sparen P, et al (2008). Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst, 100, 622-9. https://doi.org/10.1093/jnci/djn099
  2. Australian Government, Department of Health and Ageing. National cervical screening program 2014. Available from: www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/cervical-about.
  3. Canadian Task Force on Preventive Health Care, Dickinson J, Tsakonas E, et al (2013). Recommendations on screening for cervical cancer. CMAJ, 185, 35-45. https://doi.org/10.1503/cmaj.121505
  4. de Kok IM, van Rosmalen J, Dillner J, et al (2012). Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ, 344, e670. https://doi.org/10.1136/bmj.e670
  5. Fernandez ME, Savas LS, Lipizzi E, et al (2014). Cervical cancer control for Hispanic women in Texas: strategies from research and practice. Gynecol Oncol, 132, 26-32. https://doi.org/10.1016/j.ygyno.2013.12.038
  6. International Agency for Research on Cancer and World Health Organization. EUCAN (2014). Cancer incidence, mortality and prevalence. Available from: http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=25&Gender=2.
  7. Jung KW, Won YJ, Kong HJ, et al (2014). Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat, 46, 109-23. https://doi.org/10.4143/crt.2014.46.2.109
  8. Kim JJ, Andres-Beck B, Goldie SJ (2007). The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer, 97, 1322-8. https://doi.org/10.1038/sj.bjc.6604023
  9. Kim YH, Kim YJ, Kim J, et al (2013). Economic evaluation of HPV vaccination. National Evidence-based healthcare Collaborating Agency. NECA, Seoul.
  10. Lee JK, Hong JH, Kang S, et al (2013). Practice guidelines for the early detection of cervical cancer in Korea: Korean society of gynecologic oncology and the Korean society for cytopathology 2012 edition. J Gynecol Oncol, 24, 186-203. https://doi.org/10.3802/jgo.2013.24.2.186
  11. London (UK): The Service. National Health Service NHS cervical screening programme 2011. Available from: www.cancerscreening.nhs.uk/cervical
  12. Lee S, Park HT, Hong JH, et al (2013). Assessment of cervical cancer screening policy in Korea for women over age 65. J Geriatr Oncol, 4, 382-7. https://doi.org/10.1016/j.jgo.2013.03.001
  13. Lee SH, Lee Y, Kim HS, et al (2007). Analysis of clinical characteristics and prognosis in patient with recurrent cervical cancer. Korean J Obstet Gynecol, 51, 173-81.
  14. Lee YH, Choi KS, Lee HY, Jun JK (2012). Current status of the National Cancer Screening Program for cervical cancer in Korea, 2009. J Gynecol Oncol, 23, 16-21. https://doi.org/10.3802/jgo.2012.23.1.16
  15. Ministry for Health and Welfare. Annual report of cancer statistics in Korea in 2011. Available from: http://www.cancer.or.kr/
  16. Moyer VA (2012). Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Inter Med, 156, 880-91. https://doi.org/10.7326/0003-4819-156-12-201206190-00424
  17. Mun JY, Han MA, Lee HY, et al (2011). Cervical cancer screening in Korea: report on the national cancer screening programme in 2008. Asian Pac J Cancer Prev, 12, 1961-4.
  18. Nahvijou A, Hadji M, Marnani AB, et al (2014). A systematic review of economic aspects of cervical cancer screening strategies worldwide: discrepancy between economic analysis and policymaking. Asian Pac J Cancer Prev, 15, 8229-37. https://doi.org/10.7314/APJCP.2014.15.19.8229
  19. Netherlands Health council. Population screening for cervical cancer (2011). Available from: www.gezondheidsraad.nl/en/publications/population-screening-cervical-cancer.
  20. Quinn MA, Benedet JL, Odicino F, et al (2006). Carcinoma of the cervix uteri. FIGO 26th Annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet, 95, 43-103. https://doi.org/10.1016/S0020-7292(06)60030-1
  21. Shin KR, Park HJ, Bae KE, et al (2012). Sexual behavior, health risk behaviors related to reproductive health, and sexual experiences among Korean college students. J Korean Acad Adult Nurs, 22, 614-33.
  22. Sriplung H, Singkham P, Iamsirithaworn S, et al (2014). Success of a cervical cancer screening program: trends in incidence in Songkhla, southern Thailand, 1989-2010, and prediction of future incidences to 2030. Asian Pac J Cancer Prev, 15, 10003-8. https://doi.org/10.7314/APJCP.2014.15.22.10003
  23. Voko Z, Nagyjanosi L, Margitai B, et al (2012). Modeling cost-effectiveness of cervical cancer screening in Hungary. Value Health, 15, 39-45. https://doi.org/10.1016/j.jval.2011.10.003

피인용 문헌

  1. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population pp.14783223, 2018, https://doi.org/10.1111/liv.13930